Zobrazeno 1 - 10
of 591
pro vyhledávání: '"Lisa Licitra"'
Autor:
Paolo Bossi, Ester Orlandi, Carlo Resteghini, Barbara Vischioni, Piero Nicolai, Paolo Castelnuovo, Simone Gambazza, Laura D. Locati, Mario Turri-Zanoni, Marco Ferrari, Nadia Facchinetti, Nicola A. Iacovelli, Giuseppina Calareso, Pasquale Quattrone, Anna Cavallo, Alessandro Tuzi, Lisa Licitra
Publikováno v:
European Journal of Cancer. 187:134-143
Autor:
Sophie Wildsmith, Weimin Li, Song Wu, Ross Stewart, Nassim Morsli, Rajiv Raja, Qu Zhang, Jiabu Ye, Philip He, Jagdish Shetty, Alejandro Yovine, Nicholas Holoweckyj, Katia Real, Jill Walker, Magdalena Wrona, Melissa de los Reyes, Craig Barker, Jessica Whiteley, Robert Haddad, Lisa Licitra, Robert Ferris, Jérôme Fayette, Dan P. Zandberg, Lillian L. Siu, Ricard Mesía
Publikováno v:
Clinical Cancer Research. 29:2066-2074
Purpose: Biomarkers that predict response to immune checkpoint inhibitors (ICI) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) are needed. This retrospective study assessed tumor mutational burden (TMB) and outcomes in t
Autor:
Amelia Barcellini, Giulia Fontana, Daria Maria Filippini, Sara Ronchi, Maria Bonora, Barbara Vischioni, Rossana Ingargiola, Anna Maria Camarda, Pierre Loap, Nadia Facchinetti, Lisa Licitra, Guido Baroni, Ester Orlandi
Publikováno v:
Radiotherapy and Oncology. 177:143-151
In recent years, there is an emerging interest in the prognostic role of chemistry blood biomarkers in oncological patients but their role in adenoid cystic carcinomas (ACCs) is still unknown. This study aims to assess the prognostic significance of
Publikováno v:
Current Opinion in Oncology. 35:15-21
Patients with slowly progressive and/or symptomatic oligometastatic radioactive iodine refractory (RAIR) differentiated thyroid carcinomas (DTCs) are candidates to receive locoregional treatment to delay the start of systemic therapy with multikinase
Autor:
Marco Carlo Merlano, Matteo Paccagnella, Nerina Denaro, Andrea Abbona, Danilo Galizia, Dario Sangiolo, Loretta Gammaitoni, Erika Fiorino, Silvia Minei, Paolo Bossi, Lisa Licitra, Ornella Garrone
Background: Immunotherapy of head and neck cancer induces a limited but reproducible rate of long-term survivors, at the cost of treating a large number of patients exposed to toxicity without benefit, regardless of PD-L1 expression. Therefore, ident
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a68579504beb0a9ca5c03b07557a70c
https://doi.org/10.21203/rs.3.rs-2908054/v1
https://doi.org/10.21203/rs.3.rs-2908054/v1
Autor:
Ricard Mesía, Lillian L. Siu, Dan P. Zandberg, Jérôme Fayette, Robert Ferris, Lisa Licitra, Robert Haddad, Jessica Whiteley, Craig Barker, Melissa de los Reyes, Magdalena Wrona, Jill Walker, Katia Real, Nicholas Holoweckyj, Alejandro Yovine, Jagdish Shetty, Philip He, Jiabu Ye, Qu Zhang, Rajiv Raja, Nassim Morsli, Ross Stewart, Song Wu, Weimin Li, Sophie Wildsmith
FIG S2. Kaplan-Meier plot of OS in the durvalumab monotherapy, durvalumab plus tremelimumab and SoC treatment arms in the NLR ≤ 7 subgroup (A) and NLR > 7 subgroup (B) in EAGLE.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25a87e88a11e0049916dc65f88972d18
https://doi.org/10.1158/1078-0432.22551834.v1
https://doi.org/10.1158/1078-0432.22551834.v1
Autor:
Carlo Resteghini, Paolo Castelnuovo, Piero Nicolai, Ester Orlandi, Paolo Bossi, Barbara Vischioni, Alberto Schreiber, Simone Gambazza, Nicola Alessandro Iacovelli, Paolo Battaglia, Marco Guzzo, Mario Turri-Zanoni, Davide Mattavelli, Nadia Facchinetti, Giuseppina Calareso, Marco Ravanelli, Carla Facco, Tiziana Tartaro, Lisa Licitra
Publikováno v:
European Journal of Cancer.
Autor:
Sandrine Faivre, Dalila Sellami, Laurence Bourdeau, Nadia Solovieff, Ying A. Wang, Marie Chol, Andrey Karpenko, Shau-Hsuan Li, Éva Remenár, Ricard Mesía, Lisa Licitra, Denis Soulières
Purpose: The preplanned exploratory analysis of the BERIL-1 trial presented here aimed to identify biomarkers of response to the combination of buparlisib and paclitaxel.Patients and Methods: BERIL-1 was a multicenter, randomized, double-blind, place
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2abec82a34b32a259662384e7022b624
https://doi.org/10.1158/1078-0432.c.6525699
https://doi.org/10.1158/1078-0432.c.6525699
Autor:
Adel K. El-Naggar, Sue-Hwa Lin, Carlos Caulin, Randal S. Weber, Merrill S. Kies, Scott M. Lippman, Lisa Licitra, Julian C. Post, Renata Ferrarotto, Yu-Chen Lee, Sankar N. Maity, Pulivarthi H. Rao, Yoshitsugu Mitani
Supplementary Figure S1. Distribution of RET981 cell line. Supplementary Figure S2. Detection of AR splice variants in SDCs. Supplementary Figure S3. Cleaved PARP increased by AR siRNAs.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::474bfc33cd820b48719877f271a54559
https://doi.org/10.1158/1078-0432.22459587.v1
https://doi.org/10.1158/1078-0432.22459587.v1
Autor:
Maura L. Gillison, Li Li, Mark Lynch, Fernando Concha-Benavente, A. Dimitrios Colevas, Makoto Tahara, Peter Brossart, Jeffery Russell, Shanmugasundaram Ramkumar, Robert Haddad, Nabil F. Saba, Everett E. Vokes, Joel Guigay, Kevin J. Harrington, George Blumenschein, Caroline Even, Jerome Fayette, Lisa Licitra, Robert L. Ferris
Purpose:Cetuximab, which modulates immune responses, may affect the efficacy of subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior cetuximab exposure, in patients with recurrent or metastatic (R/M) squamous cell carcinoma o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14c8858f9dc86e6425bdd15ad400eea5
https://doi.org/10.1158/1078-0432.c.6527570
https://doi.org/10.1158/1078-0432.c.6527570